Pancreatic adenocarcinoma: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 9, 2010, Pages

  Tempero, Margaret A ^a   Arnoletti, J Pablo ^a   Behrman, Stephen ^a   Ben Josef, Edgar ^a   Benson III, Al B ^a   Berlin, Jordan D ^a   Cameron, John L ^a   Casper, Ephraim S ^a   Cohen, Steven J ^a   Duff, Michelle ^a   Ellenhorn, Joshua D I ^a   Hawkins, William G ^a   Hoffman, John P ^a   Kuvshinoff II, Boris W ^a   Malafa, Mokenge P ^a   Muscarella II, Peter ^a   Nakakura, Eric K ^a   Sasson, Aaron R ^a   Thayer, Sarah P ^a   Tyler, Douglas S ^a   Warren, Robert S ^a   Whiting, Samuel ^a   Willett, Christopher ^a   Wolff, Robert A ^a   more..

^a NONE

Author keywords

Adenocarcinoma; Ductal carcinoma; Endoscopic retrograde cholangiopancreatography; Gemcitabine; NCCN clinical practice guidelines; NCCN guidelines; Pancreas; Ultrasonography

Indexed keywords

2 NAPHTHYLAMINE; BENZIDINE;

ALCOHOL CONSUMPTION; BODY MASS; CANCER RISK; CHRONIC PANCREATITIS; CIGARETTE SMOKING; DAIRY PRODUCT; DIABETES MELLITUS; FOOD INTAKE; GENETIC PREDISPOSITION; HUMAN; OCCUPATIONAL EXPOSURE; PANCREAS ADENOCARCINOMA; PRACTICE GUIDELINE; RED MEAT; REVIEW; ADENOCARCINOMA; ARTICLE; GENETICS; PANCREAS TUMOR; RISK FACTOR;

ADENOCARCINOMA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 77958155207     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0073     Document Type: Review

References (250)

1. American Cancer Society. Facts & Figures 2010. Atlanta: American Chemical Society; 2010.
2. Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity. Cancer Epidemiol Biomarkers Prev 2009;18:2397-2405.
3. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009;170:403-413.
4. Raimondi S, Maisonneuve R, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708.
5. Vrieling A, Bueno-de-Mesquita HB, et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk on the European prospective investigation into cancer and nutrition. Int J Cancer 2010;126:2394-2403.
6. Thiebaut AC, Jiao L, Silverman DT, et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst 2009;101:1001-1011.
7. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 2007;120:1993-1998.
8. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009;301:2553-2562.
9. Patel AV, Rodriguez C, Bernstein L, et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:459-466. (Pubitemid 40270112)
10. Mancuso TF, el-Attar AA. Cohort study of workers exposed to beta naphthylamine and benzidine. J Occup Med 1967;9:277-285.
11. Gupta S, Vittinghoif E, Bertenthal D, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol 2006;4:1366-1372.
12. Mekan SF, Safa MM, Komrokji RS, et al. Is hyperglycemia a prognostic factor in pancreatic cancer? [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 14076.
13. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-511.
14. Pezzilli R, Casadei R, Morselli-Labate AM. Is type 2 diabetes a risk factor for pancreatic cancer? JOP 2009;10:705-706.
15. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-488.
16. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437.
17. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002;51:849-852. (Pubitemid 35408607)
18. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-275.
19. Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007;25:1417-1422. (Pubitemid 46706891)
20. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-977.
21. Ghiorzo P, Gargiulo S, Nasti S, et al. Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. J Clin Oncol 2007;25:5336-5337.
22. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-221. (Pubitemid 36240634)
23. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-438.
24. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010; in press.
25. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-621. (Pubitemid 38834045)
26. Poley JW, Klujit I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104:2175-2181.
27. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58:1410-1418.
28. Rosa JA, Van Linda BM, Abourizk NN. New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. A case report and literature review. J Clin Gastroenterol 1989;11:211-215. (Pubitemid 19104446)
29. Girelli CM, Reguzzoni G, Limido E, et al. Pancreatic carcinoma: differences between patients with or without diabetes mellitus. Recent Prog Med 1995;86:143-146.
30. Agarwal B, Abu-Hamda E, Molke KL, et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004;99:844-850. (Pubitemid 39090211)
31. Johnson CD. Pancreatic carcinoma: developing a protocol for multi-detector row CT. Radiology 2001;220:3-4.
32. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 2008;6:1301-1308.
33. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer. Ann Surg Oncol 2009;16:1727-1733.
34. House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8:280-288.
35. Klaub M, Schobinger M, Wolf I, et al. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol 2009;15:5827-5832.
36. Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167:104-111.
37. Wolff RA, Evans DB, Crane CH, et al. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma [abstract]. J Clin Oncol 2002;21(Suppl 1):Abstract 516.
38. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150-158.
39. Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:1263-1272.
40. McNulty NJ, Francis IR, Platt JF, et al. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 2001;220:97-102.
41. Schima W, Fugger R, Schober E, et al. Diagnosis and staging of pancreatic cancer: comparison of mangfodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. AJR Am J Roentgenol 2002;179:717-724.
42. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008;15:2465-2471.
43. Panwalkar A, Grem J, Hauke R, et al. Imaging in pancreatic cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 125.
44. Rosch T, Braig C, Gain T, et al. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. Gastroenterology 1992;102:188-199.
45. Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 2004;11:15-22. (Pubitemid 38595783)
46. Santo E. Pancreatic cancer imaging: which method? JOP 2004;5:253-257.
47. Inoue K, Ohuchida J, Ohtsuka T, et al. Severe localized stenosis and marked dilatation of the main pancreatic duct are indicators of pancreatic cancer instead of chronic pancreatitis on endoscopic retrograde balloon pancreatography. Gastrointest Endosc 2003;58:510-515. (Pubitemid 37205762)
48. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230-233. (Pubitemid 20060650)
49. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A 2006;16:458-463. (Pubitemid 46489517)
50. Pisters PW, Hudec WA, Hess KR, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001;234:47-55.
51. Andersson R, Vagianos CE, Williamson RC. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 2004;6:5-12. (Pubitemid 38379800)
52. Karachristos A, Scarmesas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9:1286-1292. (Pubitemid 41751121)
53. White R, Winston C, Gonen M, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008;206:445-450. (Pubitemid 351282524)
54. Ferrone CR, Haas B, Tang L, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg 2006;10:1347-1353.
55. Safi F, Roscher R, Bittner R, et al. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987;2:398-403.
56. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-479.
57. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-5503.
58. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-2902.
59. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-5922.
60. Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol, in press.
61. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-138.
62. Ishii H, Okada S, Sato T, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44:279-283.
63. Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-1016.
64. Ko AH, Hwang J, Venook AP, et al. Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-199.
65. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008;37:269-274.
66. Kalady MF, Peterson B, Baillie J, et al. Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol 2004;11:581-588.
67. Menges M, Lerch MM, Zeitz M. The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc 2000;52:74-77.
68. NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy. NIH Consens State Sci Statements 2002;19:1-26.
69. Campisi A, Brancatelli G, Vullierme MP, et al. Are pancreatic calcifications specific for the diagnosis of chronic pancreatitis? A multidetector-row CT analysis. Clin Radiol 2009;64:903-911.
70. Kajiwara M, Kojima M, Konishi M, et al. Autoimmune pancreatitis with multifocal lesions. J Hepatobiliary Pancreat Surg 2008;15:449-452.
71. Law R, Bronner M, Vogt D, Stevens T. Autoimmune pancreatitis: a mimic of pancreatic cancer. Cleve Clin J Med 2009;76:607-615.
72. Salla G, Chatzipantelis P, Lonstantinou P, et al. EUS-FNA contribution in the identification of autoimmune pancreatitis: a case report. JOP 2007;8:598-604. (Pubitemid 47455822)
73. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med 2006;355:2670-2676.
74. Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003;58:690-695. (Pubitemid 37370481)
75. Bhutani MS. Role of endoscopic ultrasonography in the diagnosis and treatment of cystic tumors of the pancreas. JOP 2004;5:266-272.
76. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010.
77. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007;110:738-744.
78. Verbeke CS. Resection margins and R1 rates in pancreatic cancer - are we there yet? Histopathology 2008;52:787-796.
79. Staley CA, Cleary KR, Abbruzzese JL, et al. The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas 1996;12:373-380.
80. Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg 1999;16:291-296.
81. Raut CP, Tseng JF, Sun CS, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52-60.
82. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-1057.
83. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-2303.
84. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358-365.
85. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-633.
86. Allison DC, Piantadosi S, Hruban RH, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151-159. (Pubitemid 28134402)
87. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
88. Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10:1338-1345.
89. Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ. Surgical management of early-stage pancreatic cancer. Cancer Control 2004;11:23-31. (Pubitemid 38595784)
90. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035-1046.
91. Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol 2006;13:1019-1020. (Pubitemid 44337960)
92. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg 1999;23:164-171.
93. Lerut JP, Gianello PR, Otte JB, Kestens PJ. Pancreaticoduodenal resection. Surgical experience and evaluation of risk factors in 103 patients. Ann Surg 1984;199:432-437.
94. Braasch JW, Gray BN. Considerations that lower pancreatoduodenectomy mortality. Am J Surg 1977;133:480-484.
95. Heslin MJ, Brooks AD, Hochwald SN, et al. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. Arch Surg 1998;133:149-154.
96. Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994;81:1195-1198.
97. McPherson GA, Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984;71:371-375.
98. Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985;201:545-553.
99. Thomas JH, Connor CS, Pierce GE, et al. Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy. Am J Surg 1984;148:727-731.
100. Hatfield AR, Tobias R, Terblanche J, et al. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982;2:896-899.
101. Gundry SR, Strodel WE, Knol JA, et al. Efficacy of preoperative biliary tract decompression in patients with obstructive jaundice. Arch Surg 1984;119:703-708. (Pubitemid 14111062)
102. Povoski SP, Karpeh MS Jr, Conlon KC, et al. Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg 1999;3:496-505.
103. Pisters PW, Hudec WA, Hess KR, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001;234:47-55.
104. van der Gaag NA, Rauws EAJ, van Eijck CHJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010;362:129-137.
105. Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959-962.
106. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-257.
107. van Berge Henegouwen MI, Moojen TM, van Gulik TM, et al. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreatoduodenectomy: the influence of tumour status. Br J Surg 1998;85:922-926.
108. Kozuschek W, Reith HB, Waleczek H, et al. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg 1994;178:443-453. (Pubitemid 24141498)
109. Seiler CA, Wagner M, Sadowski C, et al. Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): initial clinical results. J Gastrointest Surg 2000;4:443-452.
110. Morel P, Mathey P, Corboud H, et al. Pylorus-preserving duodenopancreatectomy: long-term complications and comparison with the Whipple procedure. World J Surg 1990;14:642-646. (Pubitemid 20369339)
111. Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg 1999;86:603-607. (Pubitemid 29248349)
112. Roder JD, Stein HJ, Huttl W, Siewert JR. Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152-155.
113. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580-588.
114. Sikora SS, Posner MC. Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg 1995;82:1590-1597.
115. Bassi C, Falconi M, Molinari E, et al. Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery 2003;134:766-771. (Pubitemid 37523961)
116. Strasberg SM, Drebin JA, Mokadam NA, et al. Prospective trial of a blood supply-based technique of pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure. J Am Coll Surg 2002;194:746-760.
117. Winter JM, Cameron JL, Campbell KA, et al. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2006;10:1280-1290.
118. Balcom JH, Rattner DW, Warshaw AL,et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391-398.
119. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.
120. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419-429.
121. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997;226:632-641.
122. Lillemoe KD, Cameron JL, Kim MP, et al. Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2004;8:766-772.
123. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984;199:418-425.
124. Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996;223:154-162.
125. Leach SD, Lee JE, Chamsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85:611-617.
126. Launois B, Stasik C, Bardaxoglou E, et al. Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer? World J Surg 1999;23:926-929.
127. Taschieri AM, Elli M, Rovati M, et al. Surgical treatment of pancreatic tumors invading the spleno-mesenteric-portal vessels. An Italian Multicenter Survey. Hepatogastroenterology 1999;46:492-497.
128. Clavien PA, Rudiger HA. A simple technique of portal vein resection and reconstruction during pancreaticoduodenectomy. J Am Coll Surg 1999;189:629-634.
129. van Geenen RC, ten Kate FJ, de Wit LT, et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001;129:158-163.
130. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935-949.
131. Cubilla AL, Former J, Fitzgerald PJ. Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 978;41:880-887.
132. Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986;204.65-71.
133. Pisters P, Brennan M. Regional lymph node dissection for pancreatic adenocarcinoma. In: Evans D, Pisters P, Abbruzzese J, eds. Pancreatic Cancer. New York: Springer-Verlag; 2002:139-151.
134. Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208:215-220.
135. Manabe T, Ohshio G, Baba N, et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989;64:1132-1137. (Pubitemid 19208870)
136. Geer RJ, Brennen MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
137. Henne-Bruns D, Vogel I, Luttges J, et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000;24:595-601. (Pubitemid 30210852)
138. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517.
139. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613-622.
140. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355-366.
141. Edge SB, Schmieg RE Jr, Rosenlof LK, Wilhelm MC. Pancreas cancer resection outcome in American University centers in 1989-1990. Cancer 1993;71:3502-3508.
142. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638-645.
143. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995;221:43-49.
144. Imperato PJ, Nenner RP, Starr HA, et al. The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York state. Am J Med Qual 1996;11:193-197.
145. Rosemurgy AS, Bloomston M, Serafini FM, et al. Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg 2001;5:21-26. (Pubitemid 33651234)
146. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429-438.
147. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 2003;237:509-514. (Pubitemid 38176431)
148. Simunovic M, To T, Theriault M, Langer B. Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system. CMAJ 1999;160:643-648. (Pubitemid 29149794)
149. Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786-795.
150. Birkmeyer JD, Finlayson SR, Tosteson AN, et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999;125:250-256. (Pubitemid 29168810)
151. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137. (Pubitemid 34984604)
152. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007;110:1227-1234.
153. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173-180.
154. Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
155. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782.
156. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation. Ann Surg 2007;246:734-740.
157. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
158. Koshy MC, Landry JC, Cavanaugh SX, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005;61:965-966.
159. Crane CH, Ben-Josef E, Small W Jr. Chemotherapy for pancreatic cancer. N Engl J Med 2004;350:2713-2715; author reply 2713-2715.
160. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277. (Pubitemid 46143304)
161. Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract LBA 4504.
162. Regine WF, Winter KW, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA 2008;299:1019-1026.
163. Garofalo MC, Abrams RA, Regine WF. Adjuvant therapy for pancreatic cancer: no 'definite' standard. Oncology 2007;21:726-730.
164. Neoptolemos J, Buchler M, Stocken DD, et al. ESPAC-3 (2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract LBA4505.
165. Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008;15:2773-2786.
166. Mehta VK, Poen JC, Ford JM, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155-159.
167. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-331. (Pubitemid 350003022)
168. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007;110:47-55. (Pubitemid 46986417)
169. Huguet F, Girard N, Seblain-El Guerche C, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma. J Clin Oncol 2009;27:2269-2277.
170. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226-234.
171. Quiros RM, Brown KM, Hoffman JP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest 2007;25:267-273.
172. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:317-323.
173. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
174. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-937.
175. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758-765.
176. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
177. Hoffman J P, Weese J L, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:71-77; discussion 77-78.
178. Palmer DH, Stocken DD, Buckels JA, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone vs. gemcitabine combined with cisplatin. J Clin Oncol 2007;14:2088-2096.
179. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201-1208.
180. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766-772.
181. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121-130.
182. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:2088-2096.
183. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502.
184. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-3495.
185. Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP 2007;8:279-288.
186. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710.
187. Boz G, De Paoli A, Innocente R, et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001;51:736-740.
188. Shibuya K, Oya N, Fujii T, et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 2010; in press.
189. Girard N, Mornex F, Bossard N, et al. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial. Int J Radiat Oncol Biol Phys 2010;77:1426-1432.
190. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801-808.
191. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-1302.
192. Haddock MG, Swaminathan R, Foster NR, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group phase II study N9942. J Clin Oncol 2007;25:2567-2572. (Pubitemid 47041230)
193. Ko AH, Quivey JM, Venook AP, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:809-816.
194. Klassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378.
195. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-755.
196. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4506.
197. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;18:1592-1599.
198. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413. (Pubitemid 27251144)
199. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-262.
200. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408. (Pubitemid 46594072)
201. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-3785.
202. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-485. (Pubitemid 43289750)
203. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167-175.
204. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369-376.
205. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.
206. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-2217.
207. Louvet C, Hincke A, Labianca R, Heinemann V. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 4003
208. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.
209. Louvet C, Labianca R, Hammel R, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-3516. (Pubitemid 46243495)
210. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3783. (Pubitemid 41095218)
211. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275. (Pubitemid 34831525)
212. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
213. Heinemann V, Hinke A, Boeck S, Louvet C. Benefit from gemcitabine-based combination treatment in advanced pancreatic cancer: a meta-analysis of randomized trials [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 129.
214. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-1651.
215. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-5518.
216. Stefansson OA, Jonasson JG, Johannsson OT, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.
217. Majdak EJ, Debniak J, Milczek T, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:1004-1012. (Pubitemid 41170228)
218. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-438.
219. Oliver GR, Sugar E, Laheru D, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Presented at the 2010 ASCO Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 180.
220. Berlin J, Benson AB III. Gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol 2010;7:135-137.
221. Espinza AM, Ko AH, Venook AP, et al. A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine plus capecitabine in patients with advanced pancreatic and biliary carcinomas [abstract). J Clin Oncol 2010;28(Suppl 1):Abstract 4136.
222. Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol 2009;27:5506-5512.
223. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine with gemcitabine monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587-592. (Pubitemid 44325898)
224. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-2616. (Pubitemid 41103748)
225. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-8040. (Pubitemid 46657405)
226. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 17-21, 2007; Orlando, Florida. Abstract 108.
227. Philip PA, Benedetti J, Fenoglio-Preiser M, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract LBA4509.
228. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
229. van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
230. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma: preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4010.
231. Van Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine plus nab-paclitaxel in patients with advanced metastatic pancreatic cancer: a phase I/II study [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4525.
232. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353. (Pubitemid 26246785)
233. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4508.
234. Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:3130-3136. (Pubitemid 34791103)
235. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-164. (Pubitemid 34032607)
236. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046-2052.
237. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol 2009;27:5660-5669.
238. House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am 2005;85:359-371.
239. Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006;63:986-995.
240. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006;CD004200.
241. Maire F, Hammel P, Ponsot P, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol 2006;101:735-742.
242. Lillemoe KD, Cameron JL, Hardacre JM, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230:322-328.
243. Van Heek NT, De Castro SM, van Eijck CH, et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 2003;238:894-902.
244. Wong GY, Schroeder DR, Cams PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092-1099.
245. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217:447-455; discussion 456-447.
246. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005;54(Suppl 6):1-28.
247. Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007;9:116-122.
248. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.
249. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
250. Riess H, Pelzer U, Deutschinoff G, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients with advanced pancreatic cancer: results of the CONKO 004 trial [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract LBA4506.